ESR1 and breast carcinoma: In addition, to the main effects model, the control group was simultaneously compared to the breast cancer patients stratified into two groups according to their hormonal receptor status-estrogen-positive (ER+)/progesterone-positive (PR+) tumors and estrogen-negative (ER−)/progesterone-negative (PR−) tumors.